



# Long Non-Coding RNA *CRNDE*, *LINC00957*, and *AC072061.1* as a Promising Diagnostic and Prognostic Biomarker in Glioblastoma Multiforme

Arash Poursheikhani<sup>1,2</sup>, Meysam Mosallaei<sup>3</sup>, Mohammad Foad Heidari<sup>4</sup>,  
Mohsen Rajaeinejad<sup>5</sup>, Mohsen Chamanara<sup>6,7</sup>, Mojtaba Yousefi zoshk<sup>8,9</sup>, Peyman Aslani<sup>10,11</sup>,  
Ebrahim Hazrati<sup>12</sup>, Mojgan Mohammadimehr<sup>4</sup>, \*Javad Behrouzi<sup>1,13</sup>

1. Department of Genetics and Advanced Medical Technology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
2. Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
3. Student Research Committee, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
4. Department of Laboratory Sciences, School of Allied Health Medicine, AJA University of Medical Sciences, Tehran, Iran
5. AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
6. Toxicology Research Center, AJA University of Medical Sciences, Tehran, Iran
7. Department of Pharmacology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
8. Trauma Research Center, AJA University of Medical Sciences, Tehran, Iran
9. Department of Pediatrics, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
10. Department of Parasitology and Mycology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
11. Infectious Research Center, AJA University of Medical Sciences, Tehran, Iran
12. Department of Anesthesiology and Critical Care, AJA University of Medical Sciences, Tehran, Iran
13. Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran

\*Corresponding Author: Email: Jbehrouzi.genetics@gmail.com

(Received 15 Jul 2023; accepted 21 Oct 2023)

## Abstract

**Background:** Glioblastoma multiforme (GBM) is one of the most invasive types of brain cancer. LncRNAs can be considered a new prognostic and diagnostic biomarker in GBM. This study comprehensively explored the interaction of lncRNAs with mRNAs in the TCGA database and proposed a novel promising biomarker with favorable diagnostic and prognostic values.

**Methods:** The public data of RNA-seq and related clinical data were downloaded from the TCGA database. Differential expression analysis was conducted in R. GO and KEGG signaling pathways were used for enrichment. The STRING database was used for PPI analysis. CE-network was constructed by STAR database. Kaplan-Meier survival analysis and ROC curve analysis to indicate the biomarkers' diagnostic and prognostic values.

**Results:** Differentially expressed data illustrated that 4428 mRNAs were differentially expressed in GBM. The GO and KEGG pathway analysis showed that the differentially expressed mRNAs were enriched in critical biological processes. The PPI showed that *WEE1*, *BARD1*, and *CDK6* were the important PPI hubs. The ceRNA network data demonstrated critical lncRNAs. The data revealed that the lncRNA *CRNDE*, *LINC00957*, *AC072061.1*, *AC068888.1*, and *DBH-AS1* are potential diagnostic prognostic biomarkers in the GBM patients.

**Conclusion:** Altogether, we demonstrated lncRNA, and mRNA interaction and mentioned regulatory networks, considered a therapeutic option in GBM. In addition, we proposed potential diagnostic and prognostic biomarkers for the patients.

**Keywords:** Glioblastoma multiforme; Tumorigenesis; Long non-coding RNAs



## Introduction

Glioblastoma multiforme (GBM) is one of the most invasive and dreadful types of brain cancer in adults. The incidence of GBM is 2–3 per 100.000 in Europe and North America yearly (1). GBM is also considered as a very heterogeneous cancer in the clinicopathological and molecular investigation. A dismal number of the patients survive more than 3 years with a poor prognosis (2). The average survival rate of the patient is not more than 14.6 months. Despite radical surgery, radiotherapy, and chemotherapy, treatment and diagnosis of GBM have remained so challengeable and controversial (3, 4). Majority of the patients in the late stages of GBM demonstrate TMZ resistance which causes frustrating survival rate and dismal prognosis (5). A large number of studies have shown that early diagnosis in the lower stages of GBM could improve treatment and prognosis. However, the exact underlying molecular mechanism and etiology of GBM are not entirely illustrated yet (6).

In the recent decade, numerous investigations focused on the establishment of multigene-expression signatures for GBM diagnosis, patients' classification, and also the prognosis of the disease (7, 8). Recently, long non-coding RNAs

(lncRNAs) have great potential characteristics to be a valuable biomarker for the investigation of multigene-expression signatures (9-13). LncRNAs, with more than 200 nucleotides, play main roles in many human diseases, such as different cancers. LncRNAs fine tune the expression of downstream genes by sponging miRNAs in the cancer cells (14, 15). LncRNAs contributed in numerous biological functions, such as cell proliferation, differentiation and apoptosis, inflammation, autophagy, and immunity (16).

In this study, we comprehensively considered lncRNAs, and mRNAs expressions from a public database, "Cancer Genome Atlas (TCGA)" and we constructed a ceRNA network in GBM. Furthermore, we demonstrated novel potential diagnostic and prognostic biomarkers for GBM patients.

## Materials and Methods

### Sample and data collection

The clinical data of the patients were retrieved from the TCGA database. Totally, 599 GBM were enrolled in this study. Three hundred and ten participants had age > 59 yr and 289 patients had age ≤ 59 and 366 and 230 patients were male and female, respectively (Table 1).

**Table 1:** Clinicopathological characteristics of GBM patients

<i>Characteristics</i>	<i>N</i>	<i>(%)</i>
Age (yr) (mean ± SD)	57.83	14.40
Age > 59	310	51.75
Age ≤ 59	289	48.25
Sex		
Male	366	61.10
Female	230	38.40
Not Available	3	0.50
Ethnicity		
Hispanic or Latino	13	2.17
Not Hispanic or Latino	490	81.80
Not Available	96	16.03
Race		
Asian	13	2.17
Black or African American	51	8.51
White	507	84.64
Not Available	28	4.67
Vital status		
Alive	102	17.03
Dead	492	82.14
Not Available	5	0.83

### RNA-seq data analysis

The molecular data (RNA-Seq Level 3) of GBM were downloaded from the TCGA database. The raw count of the reads of RNA-Seq data was normalized by Voom and TMM normalization methods. The “limma” package was used to indicate the differentially expressed genes. The concluded data were filtered based on the  $|\log_2$  fold change (FC)| > 1 for DEmRNA, and DELncRNA.  $P$ -value < 0.05 and false discovery rate (FDR) < 0.05 were considered as significant thresholds.

### In Silico functional enrichment analysis and protein-protein interaction (PPI) network

Gene ontology (GO) in three domains including biological processes, cellular components, and molecular functions, and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathways were used for functional enrichment analysis.

### CeRNA network construction

LncRNA-miRNA-mRNA ceRNA network was constructed by the “GDCRNATools” package in R software based on the starbase database [14].

The nodes and edges were virtualized by Cytoscape 3.7.2.


### Statistical Analysis

All the differentially expressed data were analyzed by using R software (3.5.2). Kaplan-Meier survival analysis (log-rank test) was utilized to indicate the patient’s survival time. ROC curve analysis and univariate Cox regression analysis were conducted by SPSS v21. LncRNADisease v2.0 (<http://www.rnanut.net/lncrnadisease/>) and GEPIA datasets (<http://gepia.cancer-pku.cn/>) have been utilized for linking related cancer to the lncRNAs.  $P$ -value < 0.05 was considered a significant threshold.


## Results

### Differentially Expressed Genes

Differentially expressed data illustrated that 4428 mRNA including 2582 upregulated and 1846 down-regulated were differentially expressed in GBM. Furthermore, 299 lncRNAs including 143 upregulated and 156 down-regulated were indicated as differentially expressed lncRNA in the patients. The data are shown in Figs. 1, 2 and Tables 2, 3.



**Fig. 1:** Bar graph of differentially expressed genes in the GBM samples. TEC: To be Experimentally Confirmed; TR: T cell receptor; IG: Immunoglobulin



**Fig. 2:** Volcano plot of differentially expressed genes. Up- and down-regulated genes are demonstrated in red and black, respectively

**Table 2:** Top 5 up-regulated mRNAs, and lncRNAs

<i>Protein_coding</i>			
symbol	logFC	PValue	FDR
SHOX2	8.37	0.00	0.00
HOXD10	8.31	0.00	0.00
HOXA5	8.14	0.00	0.00
NKX2-5	7.82	0.00	0.00
HOXC10	7.80	0.00	0.00
<i>Long_non_coding</i>			
symbol	logFC	PValue	FDR
AP000924.1	7.17	0.00	0.00
FOXD3-AS1	7.03	0.00	0.00
HOXA-AS2	7.02	0.00	0.00
HOXD-AS2	6.96	0.00	0.00
HOTAIR	6.22	0.00	0.00


**Table 3:** Top 5 down-regulated mRNAs, and lncRNAs

<i>Protein_coding</i>			
Symbol	logFC	PValue	FDR
GRIN1	-7.55	0.00	0.00
GABRA5	-7.25	0.00	0.00
SV2B	-7.10	0.00	0.00
PRKCG	-7.06	0.00	0.00
SLC17A7	-7.01	0.00	0.00
<i>Long_non_coding</i>			
symbol	logFC	PValue	FDR
RFPL1S	-5.21	0.00	0.00
AC023301.1	-4.92	0.00	0.00
PART1	-4.47	0.00	0.00
LINC00599	-4.32	0.00	0.00
AC107398.3	-3.83	0.00	0.00

### GO enrichment and KEGG pathway analysis

Thereby GO enrichment analysis, we indicated several prominent roles of the DEmRNAs, Biological process of GO illustrated that the DEmRNAs are majorly assigned to modulation of chemical synaptic transmission, regulation of trans-synaptic signaling, and axonogenesis, regulation of neuron. Moreover, the cellular component of GO depicted that the genes were significantly classified in neuron-to-neuron synapse,

postsynaptic specialization, and synaptic membrane. Moreover, the GO molecular function part showed that the DEmRNAs were dominantly enriched in tubulin binding, microtubule binding, and calmodulin binding (Fig. 3). Furthermore, KEGG pathway analysis showed that the DEmRNAs are remarkably attributed to Circadian entrainment, Glutamatergic synapse, and MAPK signaling pathway (Fig. 4).



**Fig. 3:** GO enrichment analysis (Biological Process, Cellular Component, Molecular Function) of the differentially expressed mRNAs in GBM patients (Top 10 GO enrichments are presented)

### PPI network construction

For a better understanding of the protein-protein interactions, we constructed a PPI network of the DEmRNAs via the STRING database. The data showed that WEE1, BARD1, CDK6 etc. were the important PPI hubs (Fig. 5). Furthermore,

the data showed that several crucial cancerous proteins which linked to the hub such as KCNC1, KCNC2, etc. Among the dominant hubs several cancer key proteins are presented such as PLK, CXCR4, GNG and SSTR.




Fig. 4: KEGG signaling pathway analysis of differentially expressed mRNAs in GBM. (Top 20 KEGG terms are presented)




Fig. 5: PPI network of the DE mRNAs in GBM (score > 0.4) with Node:57, eadge:823, MCADE score: 29.393

**LncRNA-miRNA-mRNA ceRNA network construction**

Based on the competing endogenous RNA (ceRNA) hypothesis, which explains that lncRNAs regulate mRNA expression by competing with shared miRNAs in cells, a ceRNA network was built based on the differentially expressed genes data. The ceRNA network data demonstrated critical lncRNAs including *GAS5*, *OIP5-AS1*, *AC093157.1*, *ASB16-AS1*,

*AC004656.1*, *LRPC75A-AS1*, *AC108488.1*, *HCG11*, and *NORAD* which have an important role in the development of GBM (Fig. 6). Furthermore, the data showed that miRNAs modulatory function between the lncRNAs and mRNAs. Through this ceRNA network, it has been shown miR-30, miR-137, miR-320, miR-15, miR-590, miR-144, miR-155, miR-27, miR-185, miR-330, and miR-326 have modulatory effects between critical lncRNAs and its target mRNAs.




Fig. 6: LncRNA-miRNA-mRNA ceRNA network construction of GBM. (Orange: LncRNA, Yellow: miRNA, and Green: mRNA)

**Kaplan-Meier survival analysis of differentially expressed genes**

In order to explore the association of differential expression of the genes and the GBM patient’s prognosis, a Kaplan-Meier survival analysis was

conducted over the differentially expressed genes. The data indicated that 300 mRNAs and 19 lncRNAs were associated with the overall survival rate in the patients. The top 5 hits of each group are presented in Table 4.

**Table 4:** Top 5 mRNAs, and lncRNAs that were associated with overall survival

<i>mRNA</i>				
symbol	HR	lower95	upper95	P-value
PTPRN	2.015783	1.399687	2.903063	4.75E-05
UBXN10	1.915275	1.322754	2.773213	0.000162
RPP25	1.889961	1.306174	2.734667	0.000256
LBH	1.821627	1.254755	2.644602	0.000359
NELL1	1.816388	1.266157	2.605731	0.000691
<i>LncRNA</i>				
	HR	lower95	upper95	P-value
CRNDE	1.619327	1.12814	2.324375	0.00595
LINC00957	1.612148	1.124505	2.311259	0.00717
AC072061.1	1.595938	1.115527	2.283243	0.00859
AC068888.1	1.548292	1.082151	2.215224	0.0136
DBH-AS1	1.527936	1.065361	2.191361	0.0166

**Diagnostic analysis of differentially expressed lncRNAs**

For demonstrating the diagnostic value of each DElncRNAs, AUC curve analysis was accom-

plished in the GBM samples. All 299 DElncRNAs indicated remarkable diagnostic values in the patients. The top 5 hits of the lncRNAs are presented in Table 5.

**Table 5:** Top 10 lncRNAs that had remarkable diagnostic value

<i>LncRNA</i>	<i>AUC</i>	<i>P-value</i>	<i>CI 95%</i>		<i>Expression</i>
WAC-AS1	1	0	0	0	Low
SNAI3-AS1	1	0	0	0	Low
AL158212.3	1	0	0	0	Low
AP001486.2	1	0	0	0	Low
AC005070.3	1	0	0	0	Low

**Novel Diagnostic and prognostic lncRNA biomarkers**


Hereby merging the prognostic, and the diagnostic value data, we found that 19 lncRNAs had

high ranks in prognostic and diagnostic areas, considered GBM biomarkers. The top 5 data are presented in Table 6 and Fig. 7.

**Table 6:** The lncRNAs as diagnostic and prognostic biomarkers in GBM

<i>Symbol</i>	<i>HR</i>	<i>Lower95</i>	<i>Upper95</i>	<i>P-value</i>	<i>AUC</i>	<i>P-value</i>	<i>logFC</i>	<i>P-value</i>
CRNDE	1.62	1.13	2.32	0.01	0.99	0.00	5.21	0.00
LINC00957	1.61	1.12	2.31	0.01	0.99	0.00	-2.42	0.00
AC072061.1	1.60	1.12	2.28	0.01	0.96	0.00	-1.39	0.00
AC068888.1	1.55	1.08	2.22	0.01	0.90	0.00	-1.27	0.00
DBH-AS1	1.53	1.07	2.19	0.02	0.85	0.01	-1.68	0.00





**Fig. 7:** Kaplan-Meier and ROC curve analysis. A. Kaplan-Meier curve of *CRNDE*. B. Kaplan-Meier curve of *LINC00957*. C. Kaplan-Meier curve of *AC072061.1*. D. ROC curve of the lncRNA *LINC00957* and *AC072061.1*. E. ROC curve of the lncRNA *CRNDE*.

*The lncRNAs are related to different types of cancer*

In the previous section of our study, the lncRNA *CRNDE*, *LINC00957*, and *AC072061.1* have shown promising diagnostic and prognostic values in the GBM patients. In order to illustrate the

lncRNA’s contribution to different sorts of cancer, lncRNADisease v2.0 and GEPIA datasets have been considered comprehensively. There are several studies that demonstrates the lncRNA *CRNDE*, *LINC00957*, and *AC072061.1* contributions to different cancers (Table 7).

**Table 7:** The lncRNAs and related cancers

<i>LncRNA</i>	<i>LncRNADisease v2.0</i>	<i>GEPIA</i>
<i>CRNDE</i>	colorectal cancer stomach cancer cervical cancer breast cancer Glioma gallbladder cancer malignant glioma renal cell carcinoma ovarian cancer pancreatic cancer	Adenoid Cystic Carcinoma cervical squamous cell carcinoma Colon adenocarcinoma Diffuse Large B-Cell Lymphoma Glioblastoma Kidney renal clear cell carcinoma Low-grade gliomas Liver Hepatocellular Carcinoma Pancreatic adenocarcinoma Rectum Adenocarcinoma Tenosynovial Giant Cell Tumor Thymus Cancer Uterine carcinosarcoma
<i>LINC00957</i>	-	cervical squamous cell carcinoma endocervical adenocarcinoma Glioblastoma Kidney Chromophobe Low-grade gliomas Uterine carcinosarcoma
<i>AC072061.1</i>	Lymphoma breast cancer cervical cancer colorectal cancer hepatocellular carcinoma malignant glioma melanoma neuroblastoma non-small cell lung carcinoma ovarian cancer	-

## Discussion

There is a large amount of evidence that shows lncRNA plays an important role in cell biological function. (17). A large body of studies has shown that disrupting the regulation of lncRNAs leads to cell growth, proliferation, and finally carcinogenesis (18). We showed that lncRNA expression in GBM samples has significantly changed compared to normal counterpart brain tissue. Moreover, the results showed the relationship between lncRNA, mRNA, and miRNA expression, which plays an important role in GBM pathogenicity and prognosis (19, 20). Furthermore, GO enrichment and KEGG signaling pathway analysis showed the differentially expressed genes majorly enriched in canonical pathways, particularly in tumorigenesis such as the MAPK signaling pathway. The MAPK signaling pathway is involved in various types of tumor development and progression (21, 22). Downregulation of *MALAT1* leads to cancer cell proliferation and progression, while overexpression of *MALAT1* reduces cell proliferation and invasion. The tumor suppressor effect of *MALAT1* on glioma is mediated by mitogen-activated protein kinase (MAPK) and metalloproteinase 2 (MMP2) in the cells (23).

The ceRNA network data demonstrated critical lncRNAs including *GAS5*, *OIP5-AS1*, *AC093157.1*, *ASB16-AS1*, *AC004656.1*, *LRPC75A-AS1*, *AC108488.1*, *HCG11*, and *NORAD* which have an important role in the development of GBM.

Decreased expression of lncRNA *HCG11* has been identified in GBM. Overexpression of lncRNA *HCG11* effectively inhibits cell proliferation, cell cycle, and apoptosis. lncRNA *HCG11* plays a tumor suppressor role in GBM. Analysis of the KEGG pathway showed a potential link between lncRNA *HCG11* and the Wnt signaling pathway (24). lncRNA *ASB16-AS1* drives cell proliferation, chemoresistance and stemness of the cancer cells by activating the NF- $\kappa$ B pathway. lncRNA *ASB16-AS1* has been shown to be up-regulated in NSCLC tissues and cells which con-

tributes to promoting cell proliferation and inhibits apoptosis of NSCLC cells through the Wnt/ $\beta$ -catenin signaling pathway (25).

lncRNA *GAS5* has been demonstrated as a tumor-suppressor gene in cells. Downregulation of *GAS5* could increase cell cycle promotion in the cells (17). *GAS5* is also downregulated in gastric cancer and acts as a poor prognostic factor for the survival rate of gastric cancer patients. More investigation has to be conducted to understand the exact mechanism of *GAS5* used for the diagnosis and treatment of different cancers (17).

lncRNA *NORAD* has been reported to have an important role in the development and growth of tumor cells by regulation of proliferation and migration in the cells (26). *NORAD* act as a ceRNA sponges for miR-608, and besides, upregulates the expression of *FOXO6*. *NORAD* could act as a diagnostic and prognostic biomarker for CRC. Further studies on the role of *NORAD* in tumorigenesis might be useful for therapeutic approaches to different types of cancers (26).

Wide number of studies demonstrated prominent miRNA roles in cancer (27). In the ceRNA network, we showed crucial miRNAs in cancer which play important modulatory function particularly in GBM development. MiR-30 induces cell apoptosis, and ameliorates cell proliferation and invasion in glioblastoma cells (28). MiR-137 has been demonstrated to be down-regulated in GBM patients and suppresses of *Cox-2* (29). MiR-137 inhibits cell proliferation, angiogenesis and induces differentiation of tumor stem cells of glioblastoma multiforme (30). MiR-320 acts as a tumor-suppressor miRNA in GBM cells. miR-320 inhibits cell growth and proliferation by down regulating *PBX3* and *E2F1* in glioma cells (31, 32). MiR-590 has been depicted that inhibited cell invasion, migration, and epithelial-mesenchymal transition (EMT) through Down-regulating *ZEB1* and *ZEB2* in glioblastoma multiforme cells (33). A large body of studies demonstrated anti-tumor activity of miR-144 in GBM. miR-144 inhibits cell proliferation and metastasis by targets *c-Met* in GBM (34). miR-155 has demonstrated oncogenic function in GMB

cells. miR-155 enhances cell progression and growth by augmenting Wnt/ $\beta$ -catenin pathway and suppressing GABA receptors respectively in GBM (35, 36). Numerous investigations demonstrated that miR-27 has a prominent tumorigenesis role in GBM. MiR-27 overexpression in glioma clinical samples. Furthermore miR-27 expression is associated with STAT3, c-myc and cyclin D1 expression in glioma cells (37). MiR-185 has been detected to have dominant effects on tumorigenesis of glioblastoma growth and progression. Leucine-rich repeat C4 (LRRC4) has been shown to reduce cell growth and metastasis of glioma cells by modulating miR-185- Dependent Pathway (38). Furthermore, miR155HG/miR-185/ANXA2 loop contributes to cell proliferation and progression in GBM cells (39). A large number of investigations showed that miR-330 inhibits cell progression and invasion of GBM cells through down regulation of MSI1 and ITGA5 expression of glioma (40, 41). Recently, miR-326 is associated with desired prognosis and good clinical outcome in GBM patients (42). MiR-326 is a tumor suppressor miRNA which inhibits SMO oncogene and PI3 kinase pathway in glioma cells (43, 44).

In the last part of our results, we demonstrated the lncRNA-related cancers according to the datasets. This part emphasizes on the lncRNA contributions to different cancers. Even though numerous reports explained lncRNA roles in GBM, in this work, we thoroughly presented lncRNA, miRNA, and mRNA networks and proposed a novel lncRNA-based biomarker for the patients.

## Conclusion

Altogether, in our study, we demonstrated lncRNA, miRNA, and mRNA interaction and mentioned regulatory networks, which can be considered as a therapeutic approach in GBM. In addition, the results demonstrated that the lncRNA *CRNDE*, *LINC00957*, and *AC072061.1* have potential diagnostic and prognostic characteristics for the patients.

## Journalism Ethics considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

## Conflict of interest

The authors declare that there is no conflict of interests.

## References

1. Tan L, Liu J, Yang M, Ju T, Zhang Y (2020). LncRNA ASB16-AS1 promotes proliferation and inhibits apoptosis of non small cell lung cancer cells by activating the Wnt/ $\beta$  catenin signaling pathway. *Eur Rev Med Pharmacol Sci*, 24 (4):1870-1876.
2. Sun M, Jin FY, Xia R, et al (2014). Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. *BMC Cancer*, 14:319.
3. Wang G, Lin X, Han H, et al (2022). lncRNA H19 promotes glioblastoma multiforme development by activating autophagy by sponging miR-491-5p. *Bioengineered*, 13 (5):11440-11455.
4. Wei P, Jiang J, Xiao M, et al (2022). The transcript ENST00000444125 of lncRNA LINC01503 promotes cancer stem cell properties of glioblastoma cells via reducing FBXW1 mediated GLI2 degradation. *Exp Cell Res*, 412 (1):113009.
5. Lee SY (2016). Temozolomide resistance in glioblastoma multiforme. *Genes Dis*, 3 (3):198-210.
6. Zhang L, Wang Q, Wang F, Zhang X, Tang Y, Wang S (2018). LncRNA LINC01446 promotes glioblastoma progression by modulating miR-489-3p/TPT1 axis. *Biochem Biophys Res Commun*, 503 (3):1484-1490.
7. Vojdani S, Ghaderian SMH, Zali A, et al (2021). Altered expression of EGFR and miR-34a derived from serum and tumoral tissue was

- associated with glioblastoma multiform. *Exp Mol Pathol*, 121:104655.
8. Liu S, Mitra R, Zhao MM, et al (2016). The potential roles of long noncoding RNAs (lncRNA) in glioblastoma development. *Mol Cancer Ther*, 15 (12):2977-2986.
  9. Li M, Long S, Hu J, Wang Z, Geng C, Ou S (2019). Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma. *Aging (Albany NY)*, 11 (21):9405-9423.
  10. Poursheikhani A, Abbaszadegan MR, Kerachian MA (2021). Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. *Asia Pac J Clin Oncol*, 17 (1):7-23.
  11. Poursheikhani A, Abbaszadegan MR, Nokhandani N, Kerachian MA (2020). Integration analysis of long non-coding RNA (lncRNA) role in tumorigenesis of colon adenocarcinoma. *BMC Med Genomics*, 13 (1):108.
  12. Poursheikhani A, Bahmanpour Z, Razmara E, et al (2020). Non-coding RNAs underlying chemoresistance in gastric cancer. *Cell Oncol*, 43(6):961-988.
  13. Poursheikhani A, Nokhandani N, Yousefi H, Rad DM, Sahebkar A (2020). Clinicopathological Significance of Long Non-Coding RNA GHET1 in Human Cancers: A Meta-Analysis. *Curr Pharm Biotechnol*, 21 (14):1422-1432.
  14. Liu B, Zhou J, Wang C, et al (2020). LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. *Cell Death Dis*, 11 (5):384.
  15. Poursheikhani A, Abbaszadegan MR, Kerachian MA (2022). Long non-coding RNA AC087388. 1 as a novel biomarker in colorectal cancer. *BMC Cancer*, 22 (1):196.
  16. Lv T, Jin Y, Miao Y, et al (2021). LncRNA PVT1 promotes tumorigenesis of glioblastoma by recruiting COPS5 to deubiquitinate and stabilize TRIM24. *Mol Ther Nucleic Acids*, 27:109-121.
  17. Chen X, Yan GY (2013). Novel human lncRNA-disease association inference based on lncRNA expression profiles. *Bioinformatics*, 29 (20):2617-2624.
  18. Yang G, Lu X, Yuan L (2014). LncRNA: a link between RNA and cancer. *Biochim Biophys Acta*, 1839 (11):1097-1109.
  19. Han L, Zhang K, Shi Z, et al (2012). LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. *Int J Oncol*, 40 (6):2004-2012.
  20. Yadav G, Kulshreshtha R (2022). Metastasis associated long noncoding RNAs in glioblastoma: Biomarkers and therapeutic targets. *J Cell Physiol*, 237 (1):401-420.
  21. Chen L, Gong X, Huang M (2019). YY1-activated long noncoding RNA SNHG5 promotes Glioblastoma cell proliferation through p38/MAPK signaling pathway. *Cancer Biother Radiopharm*, 34 (9):589-596.
  22. Han N, Yang L, Zhang X, et al (2019). LncRNA MATN1-AS1 prevents glioblastoma cell from proliferation and invasion via RELA regulation and MAPK signaling pathway. *Ann Transl Med*, 7 (23):784.
  23. Li J, Zhu Y, Wang H, Ji X (2018). Targeting long noncoding RNA in glioma: a pathway perspective. *Mol Ther Nucleic Acids*, 13:431-441.
  24. Chen Y, Bao C, Zhang X, Lin X, Huang H, Wang Z (2019). Long non-coding RNA HCG11 modulates glioma progression through cooperating with miR-496/CPEB3 axis. *Cell Prolif*, 52 (5):e12615.
  25. Li H, Yuan X, Yan D, et al (2017). Long non-coding RNA MALAT1 decreases the sensitivity of resistant glioblastoma cell lines to temozolomide. *Cell Physiol Biochem*, 42 (3):1192-1201.
  26. Wang L, Du L, Duan W, Yan S, Xie Y, Wang C (2018). Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression. *Oncotargets Ther*, 11:6757-6766.
  27. Bahmanpour Z, Sheervalilou R, Khaniani MS, et al (2022). In Silico and Experimental Analysis of miR-125b-5 and miR-485-5p Expression in Serum of Patients with Breast Cancer. *Microna*, 10.2174/2211536611666220523100057.
  28. Quintavalle C, Donnarumma E, Iaboni M, et al (2013). Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. *Oncogene*, 32 (34):4001-4008.

29. Chen L, Wang X, Wang H, et al (2012). miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. *Eur J Cancer*, 48 (16):3104-3111.
30. Silber J, Lim DA, Petritsch C, et al (2008). miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. *BMC Med*, 6:14.
31. Pan C, Gao H, Zheng N, Gao Q, Si Y, Zhao Y (2017). MiR-320 inhibits the growth of glioma cells through downregulating PBX3. *Biol Res*, 50 (1):31.
32. Sun JY, Xiao WZ, Wang F, et al (2015). MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1. *Mol Med Rep*, 12 (2):2355-2359.
33. Pang H, Zheng Y, Zhao Y, Xiu X, Wang J (2015). miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. *Biochem Biophys Res Commun*, 468 (4):739-745.
34. Song J, Ma Q, Hu M, Qian D, Wang B, He N (2018). The inhibition of miR-144-3p on cell proliferation and metastasis by targeting TOP2A in HCMV-positive glioblastoma cells. *Molecules*, 23 (12):3259.
35. Yan Z, Che S, Wang J, Jiao Y, Wang C, Meng Q (2015). miR-155 contributes to the progression of glioma by enhancing Wnt/ $\beta$ -catenin pathway. *Tumour Biol*, 36 (7):5323-5331.
36. D'Urso PI, D'Urso OF, Storelli C, et al (2012). miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. *Int J Oncol*, 41 (1):228-234.
37. Chen L, Li H, Han L, et al (2011). Expression and function of miR-27b in human glioma. *Oncol Rep*, 26 (6):1617-1621.
38. Tang H, Wang Z, Liu X, et al (2012). LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. *Curr Cancer Drug Targets*, 12 (8):1032-1042.
39. Wu W, Yu T, Wu Y, et al (2019). The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. *J Exp Clin Cancer Res*, 38 (1):133.
40. Feng L, Ma J, Ji H, Liu Y, Hu W (2017). miR-330-5p suppresses glioblastoma cell proliferation and invasiveness through targeting ITGA5. *Biosci Rep*, 37 (3): BSR20170019.
41. Zhu B, Liu W, Liu H, Xu Q, Xu W (2020). LINC01094 down-regulates miR-330-3p and enhances the expression of MSI1 to promote the progression of glioma. *Cancer Manag Res*, 12:6511-6521.
42. Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013). Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. *J Transl Med*, 11:10.
43. Nawaz Z, Patil V, Paul Y, et al (2016). PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA. *Mol Cancer*, 15 (1):74.
44. Du W, Liu X, Chen L, et al (2015). Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. *Neuro Oncol*, 17 (2):243-253.